PROSTIN E2 Drug Patent Profile

Which patents cover Prostin E2, and when can generic versions of Prostin E2 launch?

Prostin E2 is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in PROSTIN E2 is dinoprostone. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dinoprostone profile page.

Summary for PROSTIN E2

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	12
Patent Applications:	439
Drug Prices:	Drug price information for PROSTIN E2
DailyMed Link:	PROSTIN E2 at DailyMed

See drug prices for PROSTIN E2

Recent Clinical Trials for PROSTIN E2

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Centre Maribor	Phase 4
Aswan University Hospital	N/A
Department of Obstetrics and Gynaecology, National University Hospital	N/A

See all PROSTIN E2 clinical trials

US Patents and Regulatory Information for PROSTIN E2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	PROSTIN E2	dinoprostone	SUPPOSITORY;VAGINAL	017810-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for PROSTIN E2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	PROSTIN E2	dinoprostone	SUPPOSITORY;VAGINAL	017810-001	Approved Prior to Jan 1, 1982	3,598,858
Pfizer	PROSTIN E2	dinoprostone	SUPPOSITORY;VAGINAL	017810-001	Approved Prior to Jan 1, 1982	3,899,587

International Patents for PROSTIN E2

See the table below for patents covering PROSTIN E2 around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	126106
Sweden	305870
United Kingdom	851827
South Africa	7007763
Sweden	309648
United Kingdom	1040544
Germany	1643739	Epi-PGF,Bisdehydro-epi-PGF,Tetradehydro-epi-PGF,deren Methylester und Methylestertriacetate und Verfahren zu ihrer Herstellung

Market Dynamics and Financial Trajectory for PROSTIN E2

Last updated: February 12, 2026

Overview

PROSTIN E2 (dinoprostone) is a prostaglandin E2 analog used primarily for cervical ripening, labor induction, and termination of pregnancy. It is marketed by several pharmaceutical companies worldwide, with a primary focus on obstetrics and gynecology markets. The drug’s sales and deployment are heavily influenced by regulatory approvals, clinical guidelines, clinical demand, and regional healthcare infrastructure.

Market Size and Growth

The global market for prostaglandin-based drugs, including PROSTIN E2, was valued at approximately $200 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4%-6% through 2027, driven by increasing maternal healthcare awareness, the demand for safe labor induction agents, and expanding obstetric services in emerging markets.

• North America: Accounts for roughly 40% of the market, given high obstetric procedure volumes and widespread adoption of labor induction protocols.
• Europe: Contributes around 30%, with growth influenced by regulatory approvals and clinical practice standards.
• Asia-Pacific: Represents approximately 20%, with rapid expansion due to population growth and improving healthcare infrastructure.
• Rest of World: Comprises the remaining 10%, with variable adoption rates.

Regulatory Status and Patent Landscape

• Regulatory Approvals: PROSTIN E2 has FDA approval (since 1996) for labor induction and pregnancy termination. EU and other regional regulators approve similar indications.
• Patent and Exclusivity: The original patent has expired or is nearing expiration in several regions. Generic versions entered markets around 2005-2008, increasing price competition.
• Regulatory Challenges: New formulations or delivery mechanisms require separate approvals, potentially affecting market share stability.

Competitive Environment

• Generics: Multiple low-cost generics dominate supply, pressuring branded prices.
• New Formulations and Delivery Systems: Innovations such as controlled-release devices may extend product lifecycle and create new revenue streams.
• Alternative Agents: Misoprostol and other prostaglandins are used off-label for similar indications, impacting demand dynamics.

Market Drivers and Restraints

• Drivers:

  • Rising cesarean section rates prompt increased demand for labor induction.
  • Advances in obstetrics reduce procedure complications, improving safety profiles and adoption.
  • Growing healthcare expenditure in emerging markets expands access.

• Restraints:

  • Off-label use of alternative agents at lower costs.
  • Safety concerns related to uterine hyperstimulation and fetal distress may limit utilization.
  • Regulatory hurdles for new delivery formats.

Financial Trajectory

• Revenue Trends: With a declining branded market share due to generics, top-line revenue is expected to stabilize or slightly decline unless manufacturers innovate.

• Pricing Dynamics: Prices have dropped 30-50% since patent expiry, with generic and biosimilar competition. Manufacturers focusing on differentiation through formulation innovations may command premium pricing for new products.

• Market Entry Barriers: High regulatory requirements for new delivery forms and manufacturing complexity limit rapid entry, maintaining some pricing power for established players.

Forecast and Strategic Implications

• The market is expected to moderately grow, contingent on the adoption of new formulations and regional healthcare improvements.
• Key players may pursue licensing agreements or develop proprietary delivery devices to sustain margins.
• Generic pricing pressures are likely to persist, limiting revenue growth for branded PROSTIN E2 products.

Key Takeaways

• The global market for prostaglandin E2 drugs, including PROSTIN E2, is around $200 million, with a 4%-6% CAGR projected through 2027.
• Primary growth drivers include rising obstetric procedures, especially in emerging markets; restraints include competition from generics and alternative agents.
• Regional variations influence market dynamics, with North America and Europe dominating revenue.
• Patent expiries have increased generic competition; innovation in delivery systems could mitigate revenue decline.
• Financial prospects hinge on product differentiation, regional expansion, and regulatory navigation.

Frequently Asked Questions

1. What are the main competitors to PROSTIN E2 in the labor induction market?
   Misoprostol, dinoprostone gel, and other prostaglandin formulations.

2. How does patent expiry impact PROSTIN E2 sales?
   It enables generics, which lower prices and reduce revenue for brand-name manufacturers.

3. Are there new delivery mechanisms for PROSTIN E2?
   Yes, controlled-release devices and slow-application formulations are under development.

4. How do regional healthcare policies influence the market?
   Stricter regulations and clinical guidelines determine adoption rates and influence pricing.

5. What opportunities exist for growth in emerging markets?
   Expanding obstetric services, increasing healthcare access, and regulatory approvals facilitate market penetration.

Citations

[1] Market research reports, 2022-2023 estimates. [2] FDA approval database. [3] Industry analysis reports on obstetric pharmaceuticals. [4] Patent and generic drug market data. [5] Regional healthcare expenditure publications.